Experimental cancer drug ASP2074 trial halted early

NCT ID NCT05646797

Terminated Disease control Sponsor: Astellas Pharma Global Development, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a new drug called ASP2074 in 23 adults with advanced solid tumors that had spread or couldn't be removed by surgery. The goal was to find a safe dose and check for side effects. The study was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ASP2074 (a drug given by IV infusion)
What this could lead to: If this trial had succeeded, it could have pointed toward a new treatment option for people with certain advanced solid tumors who have run out of standard therapies.
What could go wrong: This was a very early (Phase 1) study with only 23 participants, and it was terminated early. It is unknown if ASP2074 is safe or effective, and many early cancer drugs never reach patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal adenocarcinoma esophageal adenocarcinoma gastric adenocarcinoma gastroesophageal junction adenocarcinoma metastatic malignant neoplasm neoplasm Neoplasm Metastasis pancreatic adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Aichi Cancer Center

Nagoya, Aichi-ken, Japan
Duke University

Durham, North Carolina, 27710, United States
Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
National Cancer Center Hospital

Chuo-ku, Tokyo, Japan
National Cancer Center Hospital East

Kashiwa, Chiba, Japan
Next Oncology - Oncology

San Antonio, Texas, 78229, United States
Osaka International Cancer Institute

Osaka, Japan
Rhode Island Hospital

Providence, Rhode Island, 02903, United States
START Midwest

Grand Rapids, Michigan, 49546, United States
The Cancer Institute Hospital of Japanese Foundation for Cancer Research

Koto-ku, Tokyo, Japan
University of California Davis Health System

Sacramento, California, 95817, United States
University of Iowa Hospitals

Iowa City, Iowa, 52242, United States
Virginia Mason Medical Center

Seattle, Washington, 98101, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.